NYSE:HIMS Hims & Hers Health (HIMS) Stock Price, News & Analysis $29.72 +0.59 (+2.01%) Closing price 03:59 PM EasternExtended Trading$29.35 -0.37 (-1.26%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Hims & Hers Health Stock (NYSE:HIMS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hims & Hers Health alerts:Sign Up Key Stats Today's Range$27.22▼$30.1750-Day Range$29.11▼$68.8752-Week Range$11.20▼$72.98Volume19.79 million shsAverage Volume14.31 million shsMarket Capitalization$6.60 billionP/E Ratio67.56Dividend YieldN/APrice Target$37.31Consensus RatingHold Company OverviewHims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Read More… Remove Ads Hims & Hers Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreHIMS MarketRank™: Hims & Hers Health scored higher than 75% of companies evaluated by MarketBeat, and ranked 254th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingHims & Hers Health has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 6 buy ratings, 7 hold ratings, and 2 sell ratings.Amount of Analyst CoverageHims & Hers Health has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Hims & Hers Health's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth79.31% Earnings GrowthEarnings for Hims & Hers Health are expected to grow by 79.31% in the coming year, from $0.29 to $0.52 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is 67.56, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is 67.56, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.63.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 18.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Hims & Hers Health's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted30.08% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hims & Hers Health has recently increased by 5.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted30.08% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hims & Hers Health has recently increased by 5.57%, indicating that investor sentiment is decreasing significantly. News and Social Media2.1 / 5News Sentiment0.82 News SentimentHims & Hers Health has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Hims & Hers Health this week, compared to 19 articles on an average week.Search InterestOnly 105 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat FollowsOnly 32 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -58% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,894,395.00 in company stock.Percentage Held by Insiders17.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hims & Hers Health's insider trading history. Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Email Address HIMS Stock News HeadlinesInsider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 23,287 Shares of StockMarch 19, 2025 | insidertrades.comIs Viking Therapeutics the Next Blockbuster GLP-1 Stock? (HIMS)Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.March 18, 2025 | marketbeat.comThis trading frustration almost made me quitThis happened to me time and time again, and I wanted no more of it. That’s exactly why I set out to refine my strategy… And with the help of my good friend Nate, we have done exactly that… Now, I cannot promise future returns or against losses, but the real trades so far have been nothing but astounding. Turning my once 69% win rate, into 83.3% on real trades in the last two months. And instead of just telling you, I want to SHOW you. March 31, 2025 | WealthPress (Ad)Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors (HIMS)Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.March 10, 2025 | marketbeat.comMarketBeat Week in Review – 03/03 - 03/07 (HIMS)Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continueMarch 8, 2025 | marketbeat.comIs Hims & Hers Stock Too Cheap to Pass Up?March 29 at 8:15 AM | fool.comIs Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?March 28 at 4:55 AM | fool.comWhy Hims & Hers Health Inc. (HIMS) Crashed On Wednesday?March 27, 2025 | msn.comSee More Headlines HIMS Stock Analysis - Frequently Asked Questions How have HIMS shares performed this year? Hims & Hers Health's stock was trading at $24.18 at the start of the year. Since then, HIMS shares have increased by 22.9% and is now trading at $29.7250. View the best growth stocks for 2025 here. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) released its quarterly earnings results on Monday, February, 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a trailing twelve-month return on equity of 10.97%. Who are Hims & Hers Health's major shareholders? Hims & Hers Health's top institutional investors include Vanguard Group Inc. (9.27%), Farallon Capital Management LLC (3.83%), Renaissance Technologies LLC (3.18%) and Arrowstreet Capital Limited Partnership (2.89%). Insiders that own company stock include Melissa Baird, David B Wells, Alex Bard, Patrick Harrison Carroll, Michael Chi, Andrew Dudum, Soleil Boughton, Jules A Maltz, Christopher D Payne, Oluyemi Okupe, Christiane Pendarvis, Irene Becklund, Anja Manuel and Lynne Chou O'keefe. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hims & Hers Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings2/24/2025Today3/31/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Offices & clinics of medical doctors Sub-IndustryHealthcare Current SymbolNYSE:HIMS CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees650Year FoundedN/APrice Target and Rating Average Stock Price Target$37.31 High Stock Price Target$68.00 Low Stock Price Target$20.00 Potential Upside/Downside+25.5%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$0.54 Trailing P/E Ratio67.56 Forward P/E Ratio102.50 P/E GrowthN/ANet Income$-23,550,000.00 Net Margins8.19% Pretax Margin4.16% Return on Equity10.97% Return on Assets8.29% Debt Debt-to-Equity RatioN/A Current Ratio2.14 Quick Ratio1.82 Sales & Book Value Annual Sales$1.48 billion Price / Sales4.47 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book18.46Miscellaneous Outstanding Shares222,166,000Free Float179,786,000Market Cap$6.60 billion OptionableOptionable Beta1.37 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSE:HIMS) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hims & Hers Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.